
The good news about donanemab, Eli Lilly’s Alzheimer’s drug, reached CEO Dave Ricks on July 2 as he was hiking in a remote part of Colorado.
The pharmaceutical company had slogged for 35 years and spent $8 billion to develop an effective treatment for the terrible memory-robbing disease. So when much-longed-for news of the Food and Drug Administration’s approval of the medicine finally arrived—in the middle of the Indianapolis pharmaceutical company’s annual shutdown week, with the CEO and most of his 20,000 U.S. employees on holiday—Ricks dialed into FaceTime for a quick impromptu celebration.